FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer

FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer

Source: FDA Center for Drug Evaluation and Research - What's New - July 27, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news